Table 4. Comparison of clinical and MRI data of transitional lesions.
| Clinical and MRI data | Non-clinically significant cancer (n=63) | Clinically significant cancer (n=4) |
|---|---|---|
| Age (years), mean [SD] | 73 [9] | 73 [8] |
| tPSA (ng/mL), median (IQR) | 10.03 (5.20–17.28) | 45.07 (17.19–60.85) |
| fPSA (ng/mL), median (IQR) | 1.57 (0.80–2.39) | 4.45 (2.18–6.37) |
| f/tPSA, median (IQR) | 0.17 (0.11–0.22) | 0.12 (0.08–0.21) |
| PSAD (ng/mL2), median (IQR) | 0.17 (0.11–0.31) | 0.47 (0.21–0.78) |
| PV (mL), median (IQR) | 50.00 (35.00–69.90) | 81.71 (53.88–126.75) |
| Lesion diameter (mm), mean (SD) | 19.47 (3.87) | 16.64 (1.74) |
| Lesion location, n (%) | ||
| Base | 20 (31.7) | 0 |
| Middle | 31 (49.2) | 1 (25.0) |
| Apex | 12 (19.0) | 3 (75.0) |
MRI, magnetic resonance imaging; SD, standard deviation; IQR, interquartile range; tPSA, total prostate-specific antigen; fPSA, free PSA; f/tPSA, ratio of free-to-total PSA; PSAD, PSA density; PV, prostate volume.